|
|
|
Originator Org.- |
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
洛铂联合紫杉醇治疗铂敏感型复发卵巢上皮癌的剂量探索性研究
[Translation] A dose-finding study of lobaplatin combined with paclitaxel in the treatment of platinum-sensitive recurrent epithelial ovarian cancer
通过剂量递增(剂量爬坡)试验,探索洛铂联合紫杉醇方案(TL)中洛铂的最佳剂量,为后续的多中心Ⅱ/Ⅲ期临床研究中洛铂用药剂量提供依据,并初步观察洛铂联合紫杉醇方案治疗铂敏感型复发卵巢上皮癌的有效性和安全性。
[Translation] Through a dose escalation (dose escalation) trial, the optimal dose of lobaplatin in the lobaplatin combined with paclitaxel regimen (TL) was explored to provide a basis for the dosage of lobaplatin in subsequent multicenter phase II/III clinical studies, and to preliminarily observe the efficacy and safety of the lobaplatin combined with paclitaxel regimen in the treatment of platinum-sensitive recurrent ovarian epithelial cancer.
The effectiveness and safety of lobaplatin or carboplatin combined with paclitaxel for locally advanced and metastatic non-small cell lung cancer: a prospective, dynamic randomized, positive controlled, multi-center phase Ⅲ clinical trial
The effectiveness and safety of lobaplatin or cisplatin combined with etoposide for advanced small cell lung cancer: a prospective, dynamic randomized, positive controlled, multi-center clinical trial
100 Clinical Results associated with Hainan Chang'an International Pharmaceutical Co. Ltd.
0 Patents (Medical) associated with Hainan Chang'an International Pharmaceutical Co. Ltd.
100 Deals associated with Hainan Chang'an International Pharmaceutical Co. Ltd.
100 Translational Medicine associated with Hainan Chang'an International Pharmaceutical Co. Ltd.